Brokerages Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $8.30

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.30.

A number of research analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $1.00 to $1.50 in a research report on Thursday, December 19th. Finally, Chardan Capital restated a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research note on Wednesday, February 26th.

Cognition Therapeutics Stock Down 0.5 %

Shares of Cognition Therapeutics stock opened at $0.41 on Friday. Cognition Therapeutics has a 12-month low of $0.34 and a 12-month high of $2.95. The stock has a market capitalization of $16.98 million, a P/E ratio of -0.42 and a beta of 1.04. The stock has a 50 day moving average price of $0.64 and a two-hundred day moving average price of $0.56.

Institutional Trading of Cognition Therapeutics

Several large investors have recently made changes to their positions in CGTX. BIOS Capital Management LP acquired a new stake in shares of Cognition Therapeutics in the fourth quarter valued at approximately $4,208,000. Sigma Planning Corp raised its position in shares of Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after acquiring an additional 417,300 shares during the last quarter. Voss Capital LP acquired a new position in shares of Cognition Therapeutics in the 4th quarter valued at $351,000. Geode Capital Management LLC boosted its position in shares of Cognition Therapeutics by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after purchasing an additional 28,705 shares during the last quarter. Finally, Virtu Financial LLC grew its stake in shares of Cognition Therapeutics by 40.1% during the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after purchasing an additional 22,949 shares during the period. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.